Research and Development

Showing 15 posts of 9607 posts found.

fighting_cancer

Looking to the future of oncology

April 9, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, feature, oncology, pharma

The oncology field moves so quickly that it can be hard to keep track of the latest innovations. Ben Hargreaves …
800px-prostate_cancer_1

Almost 40% of UK prostate cancer cases are diagnosed late, according to report

April 9, 2018 Medical Communications, Research and Development, Sales and Marketing Cancer, UK, pharma, prostate cancer

A report conducted by charity Orchid has revealed a “worrying trend” in the treatment of prostate cancer, indicating that as …
merckincweb

Keytruda combo fails at Phase 3 in metastatic melanoma

April 9, 2018 Research and Development, Sales and Marketing Incyte, MSD, keytruda, pharma, trial failure

Shares in biopharma firm Incyte were sent reeling by as much as 20% when the company announced that the results …
luigi_costa_credit_nordic_nanovector_headshot

Nordic Nanovector CEO steps down as company delays R&D timelines

April 5, 2018 Medical Communications, Research and Development, Sales and Marketing Luigi Costa, Nordic Nanovector, pharma

Norwegian biopharmaceutical firm Nordic Nanovector has revealed that its Chief Executive Officer Luigi Costa is set to step down from …
cystic_fibrosis_insider_interview

Transforming cystic fibrosis treatment

April 5, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Vertex, biotech, cystic fibrosis, drugs, pharma, pharmaceutical

Fred van Goor, Principle Research Fellow at Vertex Pharmaceuticals, discusses his history of work in cystic fibrosis and how the …

NICE rejects Dupixent for atopic dermatitis on cost grounds, Sanofi responds

April 4, 2018 Research and Development, Sales and Marketing Dupixent, NICE, Sanofi, atopic dermatitis, eczema, pharma

UK drug watchdog NCIE has issued draft guidance rejecting the routine use of Sanofi’s Dupixent (dupilumab) for the treatment of …
beam

Proton beam therapy finally arrives in UK

April 4, 2018 Medical Communications, Research and Development NHS, Proton beam therapy, biotech, drugs, pharma, pharmaceutical

28 years after the US first pioneered proton beam therapy at Loma Linda University Medical Center, the UK now has …
credit_ut_southwestern

Twin-drug combo effectively shrinks lung cancers by blocking their “escape route”

April 4, 2018 Research and Development Cancer, epidermal growth factor, lung cancer, pharma, tumour necrosis factor

A study conducted by researchers at UT Southwestern’s Simmons Cancer Center has revealed that a combination of two specific drug …
pfizer_chrome_plate

Pfizer running out of options for consumer business

April 4, 2018 Research and Development, Sales and Marketing P&G, Pfizer, Procter & Gamble, biotech, drugs, pharma, pharmaceutical

A surprise new name was thrown into the ring to take on Pfizer’s healthcare unit but speculation suggests that valuation …
shaking-hands-3091908_960_720

Ex-Kite execs form a CAR T rival

April 4, 2018 Research and Development, Sales and Marketing Allogene, Pfizer, biotech, drugs, pharma, pharmaceutical

After working to bring through Kite Pharma from the pre-clinical development stage to its final $12 billion acquisition by Gilead, …
fda2outsideweb

Alkermes sent reeling as FDA refuses review of depression treatment

April 3, 2018 Manufacturing and Production, Research and Development, Sales and Marketing Alkermes, FDA, depression, major depressive disorder, pharma

Alkermes shares were knocked down to their lowest level since October 2016 after it was revealed that the FDA had …
medimmune_building_cambridge

AZ’s MedImmune signs $200m immuno-oncology partnership with Compugen

April 3, 2018 Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Cancer, MedImmune, compugen, immunotherapy, oncology, pharma

AstraZeneca’s biologic R&D unit MedImmune is set to enter a partnership with Israeli drug firm Compugen to develop bi-specific and …
The Gateway to Local Adoption Series

Latest content